Utilization of EGFR, ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany.

Background: There is a lack of real-world data on the use of targeted cancer drugs requiring molecular tumor diagnostics in the treatment of lung cancer in Germany.

Aims: We aimed to characterize the use of such drugs in lung cancer patients based on longitudinal analyses.

Methods And Results: Using the GePaRD database (claims data from ~20% of the German population) we identified lung cancer patients diagnosed in 2016 based on a previously developed algorithm and followed them until death, end of continuous insurance, or end of 2019.

Age differences in the treatment of lung cancer-a cohort study among 42,000 patients from Germany.

Aims: We aimed to describe treatment of lung cancer patients in Germany based on health claims data, focusing particularly on differences by age.

Materials And Methods: Using the German Pharmacoepidemiological Research Database (GePaRD, ~ 20% of the German population) we identified lung cancer patients diagnosed in 2015-2018 based on a previously developed algorithm and followed them until death, end of continuous insurance or end of 2020. We described initial treatment patterns after diagnosis and survival, stratified among others by age.

Estimation of the Potentially Avoidable Excess Deaths Associated with Socioeconomic Inequalities in Cancer Survival in Germany.

Many countries have reported survival inequalities due to regional socioeconomic deprivation. To quantify the potential gain from eliminating cancer survival disadvantages associated with area-based deprivation in Germany, we calculated the number of avoidable excess deaths. We used population-based cancer registry data from 11 of 16 German federal states.